Document is current

Article History

Received: 11 March 2025

Accepted: 16 August 2025

First Online: 6 September 2025

Declarations

:

: Yüksel Ürün Advisory boards: Yüksel Ürün has served on advisory board for Abdi-İbrahim, Astellas, AstraZeneca, Bristol Myers-Squibb, Deva, Eczacıbaşı, Gen ilaç, Gilead, GSK, Janssen, Merck, MSD, Novartis, Pfizer, Roche Travel, Honoraria or consultation fees: Yüksel Ürün received honoraria or has served as consultant for Abdi-İbrahim, Astellas, Bristol Myers-Squibb, Deva, Eczacıbaşı, Gen İlaç, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Roche.—Fernando Sabino Monteiro Research support was provided by Foundation Medicine and Merck Sharp Dome. Honoraria from Adium, Bayer, Ipsen, Bristol Myers Squibb, Novartis and Merck Sharp Dome. Travel, Accommodations, Expenses: Ipsen, Novartis, Merck, Merck Sharp Dome and Adium. Ownership: BIO, Brazilian Information Oncology. All are unrelated to this study. Ray Manneh Kopp Clinical research: MSD, BMS, AstraZeneca, Roche, Pfizer, Novartis, Abbvie, Amgen, Jannsen. Speaker/advisory: MSD, BMS, AstraZeneca, Jannsen, Astellas, Tecnofarma, Pfizer, Ipsen, Janssen, Bayer, Eli Lilly, Roche, Novartis, Adium, Amgen, Merck Serono. Simon Crabb Fees for either speaking or advisory work from AstraZeneca, Roche, Janssen, MSD, Astellas, Amphista Therapeutics, Pfizer, Merck and Bayer; provided expert testimony for MSD, Merck and Pfizer; travel and meeting assistance from Janssen, Bayer, BMS, and Merck; and research funding support from AstraZeneca, Roche, Astex Pharmaceuticals and Clovis Oncology.